Corrigendum to 'Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study.' [EClinicalMedicine 59 (2023) 101981]

Yuming Sun; Liping Jin; Yating Dian; Minxue Shen; Furong Zeng; Xiang Chen; Guangtong Deng

doi:10.1016/j.eclinm.2023.102110

Corrigendum to 'Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study.' [EClinicalMedicine 59 (2023) 101981]

EClinicalMedicine. 2023 Jul 26:62:102110. doi: 10.1016/j.eclinm.2023.102110. eCollection 2023 Aug.

Authors

Yuming Sun^{1

2

3

4

5

6}, Liping Jin^{1

2

3

4

5}, Yating Dian^{1

2

3

4

5}, Minxue Shen^{1

2

3

4

5

7}, Furong Zeng⁸, Xiang Chen^{1

2

3

4

5}, Guangtong Deng^{1

2

3

4

5}

Affiliations

¹ Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
² National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology.
³ Furong Laboratory, Changsha, Hunan, China.
⁴ Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, China.
⁵ National Clinical Research Center for Geriatric Disorders, Xiangya Hospital.
⁶ Department of Plastic and Cosmetic Surgery, Xiangya Hospital, Central South University, Changsha, China.
⁷ Department of Social Medicine and Health Management, Xiangya School of Public Health, Central South University, Changsha, Hunan, China.
⁸ Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.

Abstract

[This corrects the article DOI: 10.1016/j.eclinm.2023.101981.].

Publication types

Published Erratum